Sunday, 27 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q1 FY27

Astec Lifesciences Q1 FY27 Results: Net Loss of ₹18.7 Cr, Loss Narrows

Astec Lifesciences Ltd reported revenue from operations of ₹83.6 Cr (-8.2% YoY) and a net loss of ₹18.7 Cr for Q1 FY27.

Q1 FY27 at a glance · ₹ crore
MetricQ1 FY27Q4 FY26Q1 FY26
Revenue from operations83.6158.691.1
Other income0.72.60.5
Total income84.3161.391.6
Profit before exceptional items & tax-18.7-7.9-33.0
Profit before tax-18.7-7.9-33.0
Net profit-18.7-7.7-33.0
Operating margin-22.2%-4.9%-36.0%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Revenue, year on year-8.20%
Operating profit, year on year+42.10%
Operating profit, quarter on quarter-88.30%
Source

BSE results filing, NSE: ASTEC. Figures extracted from the filing.

Read the filing ↗

Astec Lifesciences Ltd: key numbers

Share price
₹739.00
Market cap
₹1,647 Cr
Revenue (annual)
₹448.1 Cr
Net profit (annual)
₹-80.92 Cr
P/E (TTM)
-24.7×Sector 37.5×
Promoter holding
71.96%-0.01% QoQ
FII holding
0.01%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Astec Lifesciences Ltd

All →
10:49 IST NSE
Price Movement Clarification

Astec Lifesciences Price Movement Clarification

Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.

17:38 IST NSE
Debt & Borrowing

Astec Lifesciences Debt & Borrowing: ₹25 Cr

Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.

Value
₹25.00 Cr
10:49 IST NSE
Price Movement Clarification

Astec Lifesciences Price Movement Clarification

Astec LifeSciences replied to an NSE volume-spike surveillance notice, confirming full disclosure compliance. No undisclosed developments exist under Listing or PIT Regulations.